世界の白金抗がんAPI市場予測 2023年-2029年

◆英語タイトル：Global Platinum-based Anticancer APIs Market Growth 2023-2029

◆商品コード：LP23JU7085
◆発行会社（リサーチ会社）：LP Information
◆発行日：2023年5月（※2025年版があります。お問い合わせください。）
◆ページ数：119
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
◆産業分野：化学＆材料

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,660 ⇒換算￥527,040	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,490 ⇒換算￥790,560	見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）	USD7,320 ⇒換算￥1,054,080	見積依頼/購入/質問フォーム

★LP Informationに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の白金抗がんAPI市場」は、過去の販売実績から2022年の世界の白金抗がんAPIの総販売量を検討し、2023年から2029年の予測される白金抗がんAPIの販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の白金抗がんAPIの市場規模を掲載し、XXX百万米ドル規模の世界の白金抗がんAPI市場の詳細な分析を提供します。本インサイトレポートは、世界の白金抗がんAPI業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の白金抗がんAPI市場における各社の独自のポジションをより深く理解するために、白金抗がんAPI製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の白金抗がんAPI市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。白金抗がんAPIの米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。白金抗がんAPIの中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。白金抗がんAPIのヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

白金抗がんAPIの世界主要メーカーとしては、Jiangsu Hengrui Medicine、 Nanjing Pharmaceutical Factory、 Qilu Pharmaceutical、 Neptunus、 Hisun、 Jiangsu HaiCi biological pharmaceutical、 Kunming Guiyan Pharmaceutical、 Lingnan Pharmacy、 Jinzhou Jiutai Pharmaceutical、 Nanjing Hairun Pharmaceutical、 Simcere、 Teva、 Cipla、 Heraeus、 Hospira(Pfizer)、 Taj Pharmaceuticals、 Umicore Precious Metals Chemistryなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の白金抗がんAPI市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では白金抗がんAPI市場をセグメンテーションし、種類別 (シスプラチン、カルボプラチン、オキサリプラチン、ネダプラチン、その他)、用途別 (精巣がん、骨肉腫、乳がん、食道がん、NSCLC、その他)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：シスプラチン、カルボプラチン、オキサリプラチン、ネダプラチン、その他

・用途別区分：精巣がん、骨肉腫、乳がん、食道がん、NSCLC、その他

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の白金抗がんAPI市場の10年間の市場状況・展望は？
・世界および地域別に見た白金抗がんAPI市場成長の要因は何か？
・白金抗がんAPIの市場機会はエンドマーケットの規模によってどのように変化するのか？
・白金抗がんAPIのタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：白金抗がんAPIの年間販売量2018-2029、地域別現状・将来分析
・白金抗がんAPIの種類別セグメント：シスプラチン、カルボプラチン、オキサリプラチン、ネダプラチン、その他
・白金抗がんAPIの種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・白金抗がんAPIの用途別セグメント：精巣がん、骨肉腫、乳がん、食道がん、NSCLC、その他
・白金抗がんAPIの用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の白金抗がんAPI市場
・企業別のグローバル白金抗がんAPI市場データ：2018-2023年の年間販売量、市場シェア
・企業別の白金抗がんAPIの年間売上：2018-2023年の売上、市場シェア
・企業別の白金抗がんAPI販売価格
・主要企業の白金抗がんAPI生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

白金抗がんAPIの地域別レビュー
・地域別の白金抗がんAPI市場規模2018-2023：年間販売量、売上
・主要国別の白金抗がんAPI市場規模2018-2023：年間販売量、売上
・南北アメリカの白金抗がんAPI販売の成長
・アジア太平洋の白金抗がんAPI販売の成長
・ヨーロッパの白金抗がんAPI販売の成長
・中東・アフリカの白金抗がんAPI販売の成長

南北アメリカ市場
・南北アメリカの国別の白金抗がんAPI販売量、売上（2018-2023）
・南北アメリカの白金抗がんAPIの種類別販売量
・南北アメリカの白金抗がんAPIの用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の白金抗がんAPI販売量、売上（2018-2023）
・アジア太平洋の白金抗がんAPIの種類別販売量
・アジア太平洋の白金抗がんAPIの用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の白金抗がんAPI販売量、売上（2018-2023）
・ヨーロッパの白金抗がんAPIの種類別販売量
・ヨーロッパの白金抗がんAPIの用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の白金抗がんAPI販売量、売上（2018-2023）
・中東・アフリカの白金抗がんAPIの種類別販売量
・中東・アフリカの白金抗がんAPIの用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・白金抗がんAPIの製造コスト構造分析
・白金抗がんAPIの製造プロセス分析
・白金抗がんAPIの産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・白金抗がんAPIの主要なグローバル販売業者
・白金抗がんAPIの主要なグローバル顧客

地域別の白金抗がんAPI市場予測レビュー
・地域別の白金抗がんAPI市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・白金抗がんAPIの種類別市場規模予測
・白金抗がんAPIの用途別市場規模予測

主要企業分析
Jiangsu Hengrui Medicine、 Nanjing Pharmaceutical Factory、 Qilu Pharmaceutical、 Neptunus、 Hisun、 Jiangsu HaiCi biological pharmaceutical、 Kunming Guiyan Pharmaceutical、 Lingnan Pharmacy、 Jinzhou Jiutai Pharmaceutical、 Nanjing Hairun Pharmaceutical、 Simcere、 Teva、 Cipla、 Heraeus、 Hospira(Pfizer)、 Taj Pharmaceuticals、 Umicore Precious Metals Chemistry
・企業情報
・白金抗がんAPI製品
・白金抗がんAPI販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

LPI (LP Information)’ newest research report, the “Platinum-based Anticancer APIs Industry Forecast” looks at past sales and reviews total world Platinum-based Anticancer APIs sales in 2022, providing a comprehensive analysis by region and market sector of projected Platinum-based Anticancer APIs sales for 2023 through 2029. With Platinum-based Anticancer APIs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Platinum-based Anticancer APIs industry.
This Insight Report provides a comprehensive analysis of the global Platinum-based Anticancer APIs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Platinum-based Anticancer APIs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Platinum-based Anticancer APIs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Platinum-based Anticancer APIs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Platinum-based Anticancer APIs.
The global Platinum-based Anticancer APIs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Platinum-based Anticancer APIs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Platinum-based Anticancer APIs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Platinum-based Anticancer APIs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Platinum-based Anticancer APIs players cover Jiangsu Hengrui Medicine, Nanjing Pharmaceutical Factory, Qilu Pharmaceutical, Neptunus, Hisun, Jiangsu HaiCi biological pharmaceutical, Kunming Guiyan Pharmaceutical, Lingnan Pharmacy and Jinzhou Jiutai Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Platinum-based Anticancer APIs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Cisplatin
Carboplatin
Oxaliplatin
Nedaplatin
Others
Segmentation by application
Testicular Cancer
Osteosarcoma
Breast Cancer
Esophageal Cancer
NSCLC
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Jiangsu Hengrui Medicine
Nanjing Pharmaceutical Factory
Qilu Pharmaceutical
Neptunus
Hisun
Jiangsu HaiCi biological pharmaceutical
Kunming Guiyan Pharmaceutical
Lingnan Pharmacy
Jinzhou Jiutai Pharmaceutical
Nanjing Hairun Pharmaceutical
Simcere
Teva
Cipla
Heraeus
Hospira(Pfizer)
Taj Pharmaceuticals
Umicore Precious Metals Chemistry
Key Questions Addressed in this Report
What is the 10-year outlook for the global Platinum-based Anticancer APIs market?
What factors are driving Platinum-based Anticancer APIs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Platinum-based Anticancer APIs market opportunities vary by end market size?
How does Platinum-based Anticancer APIs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Platinum-based Anticancer APIs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Platinum-based Anticancer APIs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Platinum-based Anticancer APIs by Country/Region, 2018, 2022 & 2029
2.2 Platinum-based Anticancer APIs Segment by Type
2.2.1 Cisplatin
2.2.2 Carboplatin
2.2.3 Oxaliplatin
2.2.4 Nedaplatin
2.2.5 Others
2.3 Platinum-based Anticancer APIs Sales by Type
2.3.1 Global Platinum-based Anticancer APIs Sales Market Share by Type (2018-2023)
2.3.2 Global Platinum-based Anticancer APIs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Platinum-based Anticancer APIs Sale Price by Type (2018-2023)
2.4 Platinum-based Anticancer APIs Segment by Application
2.4.1 Testicular Cancer
2.4.2 Osteosarcoma
2.4.3 Breast Cancer
2.4.4 Esophageal Cancer
2.4.5 NSCLC
2.4.6 Other
2.5 Platinum-based Anticancer APIs Sales by Application
2.5.1 Global Platinum-based Anticancer APIs Sale Market Share by Application (2018-2023)
2.5.2 Global Platinum-based Anticancer APIs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Platinum-based Anticancer APIs Sale Price by Application (2018-2023)
3 Global Platinum-based Anticancer APIs by Company
3.1 Global Platinum-based Anticancer APIs Breakdown Data by Company
3.1.1 Global Platinum-based Anticancer APIs Annual Sales by Company (2018-2023)
3.1.2 Global Platinum-based Anticancer APIs Sales Market Share by Company (2018-2023)
3.2 Global Platinum-based Anticancer APIs Annual Revenue by Company (2018-2023)
3.2.1 Global Platinum-based Anticancer APIs Revenue by Company (2018-2023)
3.2.2 Global Platinum-based Anticancer APIs Revenue Market Share by Company (2018-2023)
3.3 Global Platinum-based Anticancer APIs Sale Price by Company
3.4 Key Manufacturers Platinum-based Anticancer APIs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Platinum-based Anticancer APIs Product Location Distribution
3.4.2 Players Platinum-based Anticancer APIs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Platinum-based Anticancer APIs by Geographic Region
4.1 World Historic Platinum-based Anticancer APIs Market Size by Geographic Region (2018-2023)
4.1.1 Global Platinum-based Anticancer APIs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Platinum-based Anticancer APIs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Platinum-based Anticancer APIs Market Size by Country/Region (2018-2023)
4.2.1 Global Platinum-based Anticancer APIs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Platinum-based Anticancer APIs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Platinum-based Anticancer APIs Sales Growth
4.4 APAC Platinum-based Anticancer APIs Sales Growth
4.5 Europe Platinum-based Anticancer APIs Sales Growth
4.6 Middle East & Africa Platinum-based Anticancer APIs Sales Growth
5 Americas
5.1 Americas Platinum-based Anticancer APIs Sales by Country
5.1.1 Americas Platinum-based Anticancer APIs Sales by Country (2018-2023)
5.1.2 Americas Platinum-based Anticancer APIs Revenue by Country (2018-2023)
5.2 Americas Platinum-based Anticancer APIs Sales by Type
5.3 Americas Platinum-based Anticancer APIs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Platinum-based Anticancer APIs Sales by Region
6.1.1 APAC Platinum-based Anticancer APIs Sales by Region (2018-2023)
6.1.2 APAC Platinum-based Anticancer APIs Revenue by Region (2018-2023)
6.2 APAC Platinum-based Anticancer APIs Sales by Type
6.3 APAC Platinum-based Anticancer APIs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Platinum-based Anticancer APIs by Country
7.1.1 Europe Platinum-based Anticancer APIs Sales by Country (2018-2023)
7.1.2 Europe Platinum-based Anticancer APIs Revenue by Country (2018-2023)
7.2 Europe Platinum-based Anticancer APIs Sales by Type
7.3 Europe Platinum-based Anticancer APIs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Platinum-based Anticancer APIs by Country
8.1.1 Middle East & Africa Platinum-based Anticancer APIs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Platinum-based Anticancer APIs Revenue by Country (2018-2023)
8.2 Middle East & Africa Platinum-based Anticancer APIs Sales by Type
8.3 Middle East & Africa Platinum-based Anticancer APIs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Platinum-based Anticancer APIs
10.3 Manufacturing Process Analysis of Platinum-based Anticancer APIs
10.4 Industry Chain Structure of Platinum-based Anticancer APIs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Platinum-based Anticancer APIs Distributors
11.3 Platinum-based Anticancer APIs Customer
12 World Forecast Review for Platinum-based Anticancer APIs by Geographic Region
12.1 Global Platinum-based Anticancer APIs Market Size Forecast by Region
12.1.1 Global Platinum-based Anticancer APIs Forecast by Region (2024-2029)
12.1.2 Global Platinum-based Anticancer APIs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Platinum-based Anticancer APIs Forecast by Type
12.7 Global Platinum-based Anticancer APIs Forecast by Application
13 Key Players Analysis
13.1 Jiangsu Hengrui Medicine
13.1.1 Jiangsu Hengrui Medicine Company Information
13.1.2 Jiangsu Hengrui Medicine Platinum-based Anticancer APIs Product Portfolios and Specifications
13.1.3 Jiangsu Hengrui Medicine Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Jiangsu Hengrui Medicine Main Business Overview
13.1.5 Jiangsu Hengrui Medicine Latest Developments
13.2 Nanjing Pharmaceutical Factory
13.2.1 Nanjing Pharmaceutical Factory Company Information
13.2.2 Nanjing Pharmaceutical Factory Platinum-based Anticancer APIs Product Portfolios and Specifications
13.2.3 Nanjing Pharmaceutical Factory Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Nanjing Pharmaceutical Factory Main Business Overview
13.2.5 Nanjing Pharmaceutical Factory Latest Developments
13.3 Qilu Pharmaceutical
13.3.1 Qilu Pharmaceutical Company Information
13.3.2 Qilu Pharmaceutical Platinum-based Anticancer APIs Product Portfolios and Specifications
13.3.3 Qilu Pharmaceutical Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Qilu Pharmaceutical Main Business Overview
13.3.5 Qilu Pharmaceutical Latest Developments
13.4 Neptunus
13.4.1 Neptunus Company Information
13.4.2 Neptunus Platinum-based Anticancer APIs Product Portfolios and Specifications
13.4.3 Neptunus Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Neptunus Main Business Overview
13.4.5 Neptunus Latest Developments
13.5 Hisun
13.5.1 Hisun Company Information
13.5.2 Hisun Platinum-based Anticancer APIs Product Portfolios and Specifications
13.5.3 Hisun Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Hisun Main Business Overview
13.5.5 Hisun Latest Developments
13.6 Jiangsu HaiCi biological pharmaceutical
13.6.1 Jiangsu HaiCi biological pharmaceutical Company Information
13.6.2 Jiangsu HaiCi biological pharmaceutical Platinum-based Anticancer APIs Product Portfolios and Specifications
13.6.3 Jiangsu HaiCi biological pharmaceutical Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Jiangsu HaiCi biological pharmaceutical Main Business Overview
13.6.5 Jiangsu HaiCi biological pharmaceutical Latest Developments
13.7 Kunming Guiyan Pharmaceutical
13.7.1 Kunming Guiyan Pharmaceutical Company Information
13.7.2 Kunming Guiyan Pharmaceutical Platinum-based Anticancer APIs Product Portfolios and Specifications
13.7.3 Kunming Guiyan Pharmaceutical Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Kunming Guiyan Pharmaceutical Main Business Overview
13.7.5 Kunming Guiyan Pharmaceutical Latest Developments
13.8 Lingnan Pharmacy
13.8.1 Lingnan Pharmacy Company Information
13.8.2 Lingnan Pharmacy Platinum-based Anticancer APIs Product Portfolios and Specifications
13.8.3 Lingnan Pharmacy Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Lingnan Pharmacy Main Business Overview
13.8.5 Lingnan Pharmacy Latest Developments
13.9 Jinzhou Jiutai Pharmaceutical
13.9.1 Jinzhou Jiutai Pharmaceutical Company Information
13.9.2 Jinzhou Jiutai Pharmaceutical Platinum-based Anticancer APIs Product Portfolios and Specifications
13.9.3 Jinzhou Jiutai Pharmaceutical Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Jinzhou Jiutai Pharmaceutical Main Business Overview
13.9.5 Jinzhou Jiutai Pharmaceutical Latest Developments
13.10 Nanjing Hairun Pharmaceutical
13.10.1 Nanjing Hairun Pharmaceutical Company Information
13.10.2 Nanjing Hairun Pharmaceutical Platinum-based Anticancer APIs Product Portfolios and Specifications
13.10.3 Nanjing Hairun Pharmaceutical Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Nanjing Hairun Pharmaceutical Main Business Overview
13.10.5 Nanjing Hairun Pharmaceutical Latest Developments
13.11 Simcere
13.11.1 Simcere Company Information
13.11.2 Simcere Platinum-based Anticancer APIs Product Portfolios and Specifications
13.11.3 Simcere Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Simcere Main Business Overview
13.11.5 Simcere Latest Developments
13.12 Teva
13.12.1 Teva Company Information
13.12.2 Teva Platinum-based Anticancer APIs Product Portfolios and Specifications
13.12.3 Teva Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Teva Main Business Overview
13.12.5 Teva Latest Developments
13.13 Cipla
13.13.1 Cipla Company Information
13.13.2 Cipla Platinum-based Anticancer APIs Product Portfolios and Specifications
13.13.3 Cipla Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Cipla Main Business Overview
13.13.5 Cipla Latest Developments
13.14 Heraeus
13.14.1 Heraeus Company Information
13.14.2 Heraeus Platinum-based Anticancer APIs Product Portfolios and Specifications
13.14.3 Heraeus Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Heraeus Main Business Overview
13.14.5 Heraeus Latest Developments
13.15 Hospira(Pfizer)
13.15.1 Hospira(Pfizer) Company Information
13.15.2 Hospira(Pfizer) Platinum-based Anticancer APIs Product Portfolios and Specifications
13.15.3 Hospira(Pfizer) Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Hospira(Pfizer) Main Business Overview
13.15.5 Hospira(Pfizer) Latest Developments
13.16 Taj Pharmaceuticals
13.16.1 Taj Pharmaceuticals Company Information
13.16.2 Taj Pharmaceuticals Platinum-based Anticancer APIs Product Portfolios and Specifications
13.16.3 Taj Pharmaceuticals Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Taj Pharmaceuticals Main Business Overview
13.16.5 Taj Pharmaceuticals Latest Developments
13.17 Umicore Precious Metals Chemistry
13.17.1 Umicore Precious Metals Chemistry Company Information
13.17.2 Umicore Precious Metals Chemistry Platinum-based Anticancer APIs Product Portfolios and Specifications
13.17.3 Umicore Precious Metals Chemistry Platinum-based Anticancer APIs Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Umicore Precious Metals Chemistry Main Business Overview
13.17.5 Umicore Precious Metals Chemistry Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Platinum-based Anticancer APIs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Platinum-based Anticancer APIs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Cisplatin
Table 4. Major Players of Carboplatin
Table 5. Major Players of Oxaliplatin
Table 6. Major Players of Nedaplatin
Table 7. Major Players of Others
Table 8. Global Platinum-based Anticancer APIs Sales by Type (2018-2023) & (Kiloton)
Table 9. Global Platinum-based Anticancer APIs Sales Market Share by Type (2018-2023)
Table 10. Global Platinum-based Anticancer APIs Revenue by Type (2018-2023) & ($ million)
Table 11. Global Platinum-based Anticancer APIs Revenue Market Share by Type (2018-2023)
Table 12. Global Platinum-based Anticancer APIs Sale Price by Type (2018-2023) & (US$/Ton)
Table 13. Global Platinum-based Anticancer APIs Sales by Application (2018-2023) & (Kiloton)
Table 14. Global Platinum-based Anticancer APIs Sales Market Share by Application (2018-2023)
Table 15. Global Platinum-based Anticancer APIs Revenue by Application (2018-2023)
Table 16. Global Platinum-based Anticancer APIs Revenue Market Share by Application (2018-2023)
Table 17. Global Platinum-based Anticancer APIs Sale Price by Application (2018-2023) & (US$/Ton)
Table 18. Global Platinum-based Anticancer APIs Sales by Company (2018-2023) & (Kiloton)
Table 19. Global Platinum-based Anticancer APIs Sales Market Share by Company (2018-2023)
Table 20. Global Platinum-based Anticancer APIs Revenue by Company (2018-2023) ($ Millions)
Table 21. Global Platinum-based Anticancer APIs Revenue Market Share by Company (2018-2023)
Table 22. Global Platinum-based Anticancer APIs Sale Price by Company (2018-2023) & (US$/Ton)
Table 23. Key Manufacturers Platinum-based Anticancer APIs Producing Area Distribution and Sales Area
Table 24. Players Platinum-based Anticancer APIs Products Offered
Table 25. Platinum-based Anticancer APIs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Platinum-based Anticancer APIs Sales by Geographic Region (2018-2023) & (Kiloton)
Table 29. Global Platinum-based Anticancer APIs Sales Market Share Geographic Region (2018-2023)
Table 30. Global Platinum-based Anticancer APIs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global Platinum-based Anticancer APIs Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global Platinum-based Anticancer APIs Sales by Country/Region (2018-2023) & (Kiloton)
Table 33. Global Platinum-based Anticancer APIs Sales Market Share by Country/Region (2018-2023)
Table 34. Global Platinum-based Anticancer APIs Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global Platinum-based Anticancer APIs Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas Platinum-based Anticancer APIs Sales by Country (2018-2023) & (Kiloton)
Table 37. Americas Platinum-based Anticancer APIs Sales Market Share by Country (2018-2023)
Table 38. Americas Platinum-based Anticancer APIs Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas Platinum-based Anticancer APIs Revenue Market Share by Country (2018-2023)
Table 40. Americas Platinum-based Anticancer APIs Sales by Type (2018-2023) & (Kiloton)
Table 41. Americas Platinum-based Anticancer APIs Sales by Application (2018-2023) & (Kiloton)
Table 42. APAC Platinum-based Anticancer APIs Sales by Region (2018-2023) & (Kiloton)
Table 43. APAC Platinum-based Anticancer APIs Sales Market Share by Region (2018-2023)
Table 44. APAC Platinum-based Anticancer APIs Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC Platinum-based Anticancer APIs Revenue Market Share by Region (2018-2023)
Table 46. APAC Platinum-based Anticancer APIs Sales by Type (2018-2023) & (Kiloton)
Table 47. APAC Platinum-based Anticancer APIs Sales by Application (2018-2023) & (Kiloton)
Table 48. Europe Platinum-based Anticancer APIs Sales by Country (2018-2023) & (Kiloton)
Table 49. Europe Platinum-based Anticancer APIs Sales Market Share by Country (2018-2023)
Table 50. Europe Platinum-based Anticancer APIs Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe Platinum-based Anticancer APIs Revenue Market Share by Country (2018-2023)
Table 52. Europe Platinum-based Anticancer APIs Sales by Type (2018-2023) & (Kiloton)
Table 53. Europe Platinum-based Anticancer APIs Sales by Application (2018-2023) & (Kiloton)
Table 54. Middle East & Africa Platinum-based Anticancer APIs Sales by Country (2018-2023) & (Kiloton)
Table 55. Middle East & Africa Platinum-based Anticancer APIs Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa Platinum-based Anticancer APIs Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa Platinum-based Anticancer APIs Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa Platinum-based Anticancer APIs Sales by Type (2018-2023) & (Kiloton)
Table 59. Middle East & Africa Platinum-based Anticancer APIs Sales by Application (2018-2023) & (Kiloton)
Table 60. Key Market Drivers & Growth Opportunities of Platinum-based Anticancer APIs
Table 61. Key Market Challenges & Risks of Platinum-based Anticancer APIs
Table 62. Key Industry Trends of Platinum-based Anticancer APIs
Table 63. Platinum-based Anticancer APIs Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Platinum-based Anticancer APIs Distributors List
Table 66. Platinum-based Anticancer APIs Customer List
Table 67. Global Platinum-based Anticancer APIs Sales Forecast by Region (2024-2029) & (Kiloton)
Table 68. Global Platinum-based Anticancer APIs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas Platinum-based Anticancer APIs Sales Forecast by Country (2024-2029) & (Kiloton)
Table 70. Americas Platinum-based Anticancer APIs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC Platinum-based Anticancer APIs Sales Forecast by Region (2024-2029) & (Kiloton)
Table 72. APAC Platinum-based Anticancer APIs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe Platinum-based Anticancer APIs Sales Forecast by Country (2024-2029) & (Kiloton)
Table 74. Europe Platinum-based Anticancer APIs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa Platinum-based Anticancer APIs Sales Forecast by Country (2024-2029) & (Kiloton)
Table 76. Middle East & Africa Platinum-based Anticancer APIs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global Platinum-based Anticancer APIs Sales Forecast by Type (2024-2029) & (Kiloton)
Table 78. Global Platinum-based Anticancer APIs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global Platinum-based Anticancer APIs Sales Forecast by Application (2024-2029) & (Kiloton)
Table 80. Global Platinum-based Anticancer APIs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. Jiangsu Hengrui Medicine Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 82. Jiangsu Hengrui Medicine Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 83. Jiangsu Hengrui Medicine Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 84. Jiangsu Hengrui Medicine Main Business
Table 85. Jiangsu Hengrui Medicine Latest Developments
Table 86. Nanjing Pharmaceutical Factory Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 87. Nanjing Pharmaceutical Factory Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 88. Nanjing Pharmaceutical Factory Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 89. Nanjing Pharmaceutical Factory Main Business
Table 90. Nanjing Pharmaceutical Factory Latest Developments
Table 91. Qilu Pharmaceutical Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 92. Qilu Pharmaceutical Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 93. Qilu Pharmaceutical Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 94. Qilu Pharmaceutical Main Business
Table 95. Qilu Pharmaceutical Latest Developments
Table 96. Neptunus Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 97. Neptunus Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 98. Neptunus Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 99. Neptunus Main Business
Table 100. Neptunus Latest Developments
Table 101. Hisun Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 102. Hisun Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 103. Hisun Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 104. Hisun Main Business
Table 105. Hisun Latest Developments
Table 106. Jiangsu HaiCi biological pharmaceutical Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 107. Jiangsu HaiCi biological pharmaceutical Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 108. Jiangsu HaiCi biological pharmaceutical Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 109. Jiangsu HaiCi biological pharmaceutical Main Business
Table 110. Jiangsu HaiCi biological pharmaceutical Latest Developments
Table 111. Kunming Guiyan Pharmaceutical Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 112. Kunming Guiyan Pharmaceutical Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 113. Kunming Guiyan Pharmaceutical Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 114. Kunming Guiyan Pharmaceutical Main Business
Table 115. Kunming Guiyan Pharmaceutical Latest Developments
Table 116. Lingnan Pharmacy Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 117. Lingnan Pharmacy Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 118. Lingnan Pharmacy Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 119. Lingnan Pharmacy Main Business
Table 120. Lingnan Pharmacy Latest Developments
Table 121. Jinzhou Jiutai Pharmaceutical Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 122. Jinzhou Jiutai Pharmaceutical Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 123. Jinzhou Jiutai Pharmaceutical Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 124. Jinzhou Jiutai Pharmaceutical Main Business
Table 125. Jinzhou Jiutai Pharmaceutical Latest Developments
Table 126. Nanjing Hairun Pharmaceutical Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 127. Nanjing Hairun Pharmaceutical Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 128. Nanjing Hairun Pharmaceutical Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 129. Nanjing Hairun Pharmaceutical Main Business
Table 130. Nanjing Hairun Pharmaceutical Latest Developments
Table 131. Simcere Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 132. Simcere Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 133. Simcere Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 134. Simcere Main Business
Table 135. Simcere Latest Developments
Table 136. Teva Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 137. Teva Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 138. Teva Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 139. Teva Main Business
Table 140. Teva Latest Developments
Table 141. Cipla Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 142. Cipla Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 143. Cipla Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 144. Cipla Main Business
Table 145. Cipla Latest Developments
Table 146. Heraeus Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 147. Heraeus Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 148. Heraeus Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 149. Heraeus Main Business
Table 150. Heraeus Latest Developments
Table 151. Hospira(Pfizer) Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 152. Hospira(Pfizer) Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 153. Hospira(Pfizer) Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 154. Hospira(Pfizer) Main Business
Table 155. Hospira(Pfizer) Latest Developments
Table 156. Taj Pharmaceuticals Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 157. Taj Pharmaceuticals Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 158. Taj Pharmaceuticals Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 159. Taj Pharmaceuticals Main Business
Table 160. Taj Pharmaceuticals Latest Developments
Table 161. Umicore Precious Metals Chemistry Basic Information, Platinum-based Anticancer APIs Manufacturing Base, Sales Area and Its Competitors
Table 162. Umicore Precious Metals Chemistry Platinum-based Anticancer APIs Product Portfolios and Specifications
Table 163. Umicore Precious Metals Chemistry Platinum-based Anticancer APIs Sales (Kiloton), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2018-2023)
Table 164. Umicore Precious Metals Chemistry Main Business
Table 165. Umicore Precious Metals Chemistry Latest Developments
List of Figures
Figure 1. Picture of Platinum-based Anticancer APIs
Figure 2. Platinum-based Anticancer APIs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Platinum-based Anticancer APIs Sales Growth Rate 2018-2029 (Kiloton)
Figure 7. Global Platinum-based Anticancer APIs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Platinum-based Anticancer APIs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Cisplatin
Figure 10. Product Picture of Carboplatin
Figure 11. Product Picture of Oxaliplatin
Figure 12. Product Picture of Nedaplatin
Figure 13. Product Picture of Others
Figure 14. Global Platinum-based Anticancer APIs Sales Market Share by Type in 2022
Figure 15. Global Platinum-based Anticancer APIs Revenue Market Share by Type (2018-2023)
Figure 16. Platinum-based Anticancer APIs Consumed in Testicular Cancer
Figure 17. Global Platinum-based Anticancer APIs Market: Testicular Cancer (2018-2023) & (Kiloton)
Figure 18. Platinum-based Anticancer APIs Consumed in Osteosarcoma
Figure 19. Global Platinum-based Anticancer APIs Market: Osteosarcoma (2018-2023) & (Kiloton)
Figure 20. Platinum-based Anticancer APIs Consumed in Breast Cancer
Figure 21. Global Platinum-based Anticancer APIs Market: Breast Cancer (2018-2023) & (Kiloton)
Figure 22. Platinum-based Anticancer APIs Consumed in Esophageal Cancer
Figure 23. Global Platinum-based Anticancer APIs Market: Esophageal Cancer (2018-2023) & (Kiloton)
Figure 24. Platinum-based Anticancer APIs Consumed in NSCLC
Figure 25. Global Platinum-based Anticancer APIs Market: NSCLC (2018-2023) & (Kiloton)
Figure 26. Platinum-based Anticancer APIs Consumed in Other
Figure 27. Global Platinum-based Anticancer APIs Market: Other (2018-2023) & (Kiloton)
Figure 28. Global Platinum-based Anticancer APIs Sales Market Share by Application (2022)
Figure 29. Global Platinum-based Anticancer APIs Revenue Market Share by Application in 2022
Figure 30. Platinum-based Anticancer APIs Sales Market by Company in 2022 (Kiloton)
Figure 31. Global Platinum-based Anticancer APIs Sales Market Share by Company in 2022
Figure 32. Platinum-based Anticancer APIs Revenue Market by Company in 2022 ($ Million)
Figure 33. Global Platinum-based Anticancer APIs Revenue Market Share by Company in 2022
Figure 34. Global Platinum-based Anticancer APIs Sales Market Share by Geographic Region (2018-2023)
Figure 35. Global Platinum-based Anticancer APIs Revenue Market Share by Geographic Region in 2022
Figure 36. Americas Platinum-based Anticancer APIs Sales 2018-2023 (Kiloton)
Figure 37. Americas Platinum-based Anticancer APIs Revenue 2018-2023 ($ Millions)
Figure 38. APAC Platinum-based Anticancer APIs Sales 2018-2023 (Kiloton)
Figure 39. APAC Platinum-based Anticancer APIs Revenue 2018-2023 ($ Millions)
Figure 40. Europe Platinum-based Anticancer APIs Sales 2018-2023 (Kiloton)
Figure 41. Europe Platinum-based Anticancer APIs Revenue 2018-2023 ($ Millions)
Figure 42. Middle East & Africa Platinum-based Anticancer APIs Sales 2018-2023 (Kiloton)
Figure 43. Middle East & Africa Platinum-based Anticancer APIs Revenue 2018-2023 ($ Millions)
Figure 44. Americas Platinum-based Anticancer APIs Sales Market Share by Country in 2022
Figure 45. Americas Platinum-based Anticancer APIs Revenue Market Share by Country in 2022
Figure 46. Americas Platinum-based Anticancer APIs Sales Market Share by Type (2018-2023)
Figure 47. Americas Platinum-based Anticancer APIs Sales Market Share by Application (2018-2023)
Figure 48. United States Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 49. Canada Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 50. Mexico Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 51. Brazil Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 52. APAC Platinum-based Anticancer APIs Sales Market Share by Region in 2022
Figure 53. APAC Platinum-based Anticancer APIs Revenue Market Share by Regions in 2022
Figure 54. APAC Platinum-based Anticancer APIs Sales Market Share by Type (2018-2023)
Figure 55. APAC Platinum-based Anticancer APIs Sales Market Share by Application (2018-2023)
Figure 56. China Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 57. Japan Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 58. South Korea Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 59. Southeast Asia Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 60. India Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 61. Australia Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 62. China Taiwan Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 63. Europe Platinum-based Anticancer APIs Sales Market Share by Country in 2022
Figure 64. Europe Platinum-based Anticancer APIs Revenue Market Share by Country in 2022
Figure 65. Europe Platinum-based Anticancer APIs Sales Market Share by Type (2018-2023)
Figure 66. Europe Platinum-based Anticancer APIs Sales Market Share by Application (2018-2023)
Figure 67. Germany Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 68. France Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 69. UK Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 70. Italy Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 71. Russia Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 72. Middle East & Africa Platinum-based Anticancer APIs Sales Market Share by Country in 2022
Figure 73. Middle East & Africa Platinum-based Anticancer APIs Revenue Market Share by Country in 2022
Figure 74. Middle East & Africa Platinum-based Anticancer APIs Sales Market Share by Type (2018-2023)
Figure 75. Middle East & Africa Platinum-based Anticancer APIs Sales Market Share by Application (2018-2023)
Figure 76. Egypt Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 77. South Africa Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 78. Israel Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 79. Turkey Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 80. GCC Country Platinum-based Anticancer APIs Revenue Growth 2018-2023 ($ Millions)
Figure 81. Manufacturing Cost Structure Analysis of Platinum-based Anticancer APIs in 2022
Figure 82. Manufacturing Process Analysis of Platinum-based Anticancer APIs
Figure 83. Industry Chain Structure of Platinum-based Anticancer APIs
Figure 84. Channels of Distribution
Figure 85. Global Platinum-based Anticancer APIs Sales Market Forecast by Region (2024-2029)
Figure 86. Global Platinum-based Anticancer APIs Revenue Market Share Forecast by Region (2024-2029)
Figure 87. Global Platinum-based Anticancer APIs Sales Market Share Forecast by Type (2024-2029)
Figure 88. Global Platinum-based Anticancer APIs Revenue Market Share Forecast by Type (2024-2029)
Figure 89. Global Platinum-based Anticancer APIs Sales Market Share Forecast by Application (2024-2029)
Figure 90. Global Platinum-based Anticancer APIs Revenue Market Share Forecast by Application (2024-2029)

※参考情報

白金抗がんAPI（Platinum-based Anticancer APIs）は、抗がん剤の一種であり、主に白金（プラチナ）を含む化合物を基盤としています。これらの化合物は、特定の癌細胞に対して効果を示すことから、腫瘍の治療に広く用いられています。白金ベースの抗がん剤は、特に肺癌、卵巣癌、膀胱癌など、さまざまな種類の癌に対して適応されることが多いです。

白金抗がんAPIの特徴として、まずはそのメカニズムがあります。白金系化合物は、DNAに結合することにより、細胞の分裂を妨げ、最終的には癌細胞の死を引き起こします。この結合から生成されるDNA 欠損や修復の障害は、細胞周期の進行を停止させ、癌細胞の増殖を抑制します。また、正常細胞とは異なる癌細胞の特性を利用して、治療効果を高めることができる点も特徴の一つです。

白金抗がんAPIの代表的な種類としては、シスプラチン、カルボプラチン、オキサリプラチンといった化合物が挙げられます。シスプラチンは1960年代に初めて臨床使用され、その効果により多くの癌治療に利用されるようになりました。次に開発されたカルボプラチンは、シスプラチンの副作用を軽減しつつ、同様の抗腫瘍効果を持つことから、多くの治療法に組み込まれています。オキサリプラチンは、特に大腸癌に対する有効性が報告されており、これらの化合物はそれぞれ異なる副作用プロファイルを持つため、患者の状態や腫瘍の特性に応じた適切な選択が求められます。

白金抗がんAPIの用途は非常に広範で、特に固形腫瘍に対して多く使用されています。シスプラチンは肺癌や卵巣癌、頭頸部癌などの治療に利用されます。一方、カルボプラチンは同じく卵巣癌に加え、非小細胞肺癌や膀胱癌の治療にも用いられています。オキサリプラチンは主に大腸癌の治療に用いられることが多いですが、その独特な作用機序から、他の癌種にも応用されることがあります。

関連技術としては、白金抗がんAPIの効果を最大限に引き出すための薬物送達システムや、その他の抗がん剤との併用療法が重要な分野です。ナノテクノロジーを利用した薬物送達システムにより、白金系化合物を効果的に腫瘍組織に届けることが可能となります。この方法は、副作用を最小限に抑えつつ、治療効果を高めることを目的としています。

さらに、分子標的治療や免疫療法との併用も研究されており、これにより抗がん剤の効果を更に上昇させることが期待されています。また、白金系化合物に対する耐性の問題も重要であり、研究者は耐性機序を解明し、新たな治療法の開発に努めています。耐性を克服するための新しい薬剤の開発、新しい投与方法、既存の薬剤との組み合わせ療法が活発に研究されています。

このように、白金抗がんAPIは、医学の進歩とともにその適用範囲が拡大し続けています。今後も新たな研究や技術革新が期待され、さらなる浸透と利用の拡大が見込まれています。白金系抗がん剤は、癌治療の現場において貴重な資源であると同時に、今後の研究によってより効果的な治療法として進化していくことでしょう。患者のQOL（生活の質）を向上させるための新たなソリューションとして、白金抗がんAPIは重要な役割を果たすことでしょう。これからも医療関係者や研究者が協力し、より効果的な治療法を追求していくことが求められます。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の白金抗がんAPI市場予測 2023年-2029年(Global Platinum-based Anticancer APIs Market Growth 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の白金抗がんAPI市場予測 2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp